Global Blood Therapeutics Inc.

NASDAQ:GBT   3:59:50 PM EDT
27.46
-1.53 (-5.28%)
Products, Regulatory

Gbt Presents Positive Results From Phase 1 Study Of Gbt021601 In Patients With Sickle Cell Disease And Healthy Volunteers At Ash Annual Meeting And Exposition

Published: 12/13/2021 14:50 GMT
Global Blood Therapeutics Inc. (GBT) - Gbt Presents Positive Results From Phase 1 Study of Gbt021601 in Patients With Sickle Cell Disease and Healthy Volunteers at Ash Annual Meeting and Exposition.
Global Blood Therapeutics - Study Results Provide Proof of Concept to Support Continued Development of Gbt601.
Global Blood Therapeutics - Gbt601 Tolerability Was Favorable in Studies of Scd Patients and Healthy Volunteers.